Effect of Feeding Jejunostomy on Sarcopenia in Patients with Esophageal Cancer

Stefan Gutknecht

Status: Not yet enrolling

Conditions: Feeding Tube; Esophageal Carcinoma; Esophageal Cancer; Sarcopenia

Treatments: Procedure: Feeding jejunostomy placement at esophagectomy; Procedure: Feeding jejunostomy placement

Study type: Observational

Funder types: Other

Identifiers

NCT06712706

BASEC 2024-01793

Details and patient eligibility

About

Participants were diagnosed with esophageal cancer needing chemo- or radiochemotherapy before the potentially curing surgery consisting of esophagectomy. At the time of diagnosis, in all participants, a laparoscopy to complete staging was performed. In some patients, a feeding jejunostomy tube (FJT) was placed at the time of staging laparoscopy; in others, the FJT was placed at the time of esophagectomy. A common risk factor for higher morbidity and mortality is sarcopenia, a condition associated with low skeletal muscle. This study aims to determine whether the timing of the FJT placement affects the progress of sarcopenia.

Full description

At the City Hospital Zurich Triemli, an FJT tube is inserted in approximately two-thirds of patients before commencing neoadjuvant therapy. Another third receive an FJT at the time of esophagectomy to ensure postoperative enteral feeding. To this day, no prospective, randomized study exists as to whether placing an FJT at diagnosis or esophagectomy impacts sarcopenia. Retrospectively collected data is limited due to small sample sizes and observational character.

This is a retrospective, single-center cohort study using disease-related data already collected. The study design includes statistical balancing techniques to achieve comparability between the two groups and estimate an unbiased treatment effect of the timing of FJT placement.

All data is extracted from the clinical information systems and radiological systems and is credible, protected data. It is taken exclusively from the medical records; patients are not contacted for data collection.

Enrollment: 70 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients aged 18 years and above at the time of diagnosis.
• Advanced-stage esophageal cancer or cancer of the esophageal junction and treated with curative intent, including neoadjuvant treatment.
• Patients who received an FJT either before neoadjuvant treatment or during definitive surgery.

Exclusion criteria

• Insufficient data for analysis
• Written rejection of general consent

Trial design

70 participants in 1 patient group

Patients with esophageal cancer receiving neoadjuvant therapy and an jejunal feeding tube

Description:

Included are: * Adult patients aged 18 years and above at the time of diagnosis. * Advanced-stage esophageal cancer or cancer of the esophageal junction and treated with curative intent, including neoadjuvant treatment. * Patients who received an FJT before neoadjuvant treatment or during definitive surgery. * Patients treated between 2017 and 2024 in the single institution of the City Hospital Zürich Triemli and completed 6 months of follow-up or died by 31.12.2024. Patients receiving the FJT at staging laparoscopy will be compared to patients receiving FJT at the time of esophagectomy.

Treatment:

Procedure: Feeding jejunostomy placement

Procedure: Feeding jejunostomy placement at esophagectomy